XF-73 Nasal is the lead asset from the company’s XF platform
...
…and is a novel compound being developed for the prevention of post-surgical Staphylococcal infections. XF-73 reported very positive clinical data in 2021.
NTCD-M3, our lead biotherapeutic asset, targets CDI. The company owns global rights to the world’s most advanced single strain, live biotherapeutic product
...
…which is the non-toxigenic Clostridioides difficile strain M3 – for the prevention of recurring C. difficile gut infections (CDI).